Literature DB >> 23403990

The effectiveness of the oncolytic activity induced by Ad5/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy.

So Y Kim1, Sujin Kang, Jae J Song, Joo-Hang Kim.   

Abstract

To overcome the poor tumor transduction efficiency of adenovirus serotype 5 (Ad5) observed in several types of cancer, the fiber region of Ad5, apart from its tail, was replaced by adenovirus serotype 35 (Ad35). The chimeric Ad5/F35 adenoviral vector did not exhibit any significant enhancement of transduction efficiency. CD46, a receptor for Ad35, was expressed in relatively small amounts in most of the cancer cells examined. Therefore, we investigated the pivotal factor(s) that render cancer cells susceptible to transduction. We discovered that the tumor transduction efficiency of Ad5/F35 was enhanced in the presence of rapamycin, an autophagy inducer, in some cancer cells. Analysis of survival potential and cell proliferation rates revealed that Ad5/F35 exerted a more pronounced oncolytic effect in cancer cells with higher survival potential in the presence of rapamycin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23403990     DOI: 10.3892/ijo.2013.1812

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

Review 1.  A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy.

Authors:  Ming Yang; Chun Sheng Yang; WenWen Guo; JianQin Tang; Qian Huang; ShouXin Feng; AiJun Jiang; XiFeng Xu; Guan Jiang; Yan Qun Liu
Journal:  Cancer Biol Ther       Date:  2017-11-16       Impact factor: 4.742

2.  Adenovirus co-expressing CD40 ligand and interleukin (IL)-2 contributes to maturation of dendritic cells and production of IL-12.

Authors:  Zhi Guo; Hong-Yan Gao; Tian-Yang Zhang; Jin-Xing Lou; Kai Yang; Xiao-Dong Liu; Xue-Peng He; Hui-Ren Chen
Journal:  Biomed Rep       Date:  2016-10-06

3.  Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors.

Authors:  Yinghan Su; Jiang Li; Weidan Ji; Gang Wang; Lin Fang; Qin Zhang; Lin Ang; Min Zhao; Yuan Sen; Lei Chen; Junnian Zheng; Changqing Su; Lunxiu Qin
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

4.  Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes.

Authors:  Suguru Yamauchi; Boya Zhong; Kiyoko Kawamura; Shan Yang; Shuji Kubo; Masato Shingyoji; Ikuo Sekine; Yuji Tada; Koichiro Tatsumi; Hideaki Shimada; Kenzo Hiroshima; Masatoshi Tagawa
Journal:  BMC Cancer       Date:  2017-09-05       Impact factor: 4.430

5.  Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.

Authors:  So Young Kim; Dongxu Kang; Hye Jin Choi; Yeonsoo Joo; Joo-Hang Kim; Jae J Song
Journal:  Oncotarget       Date:  2017-02-28

6.  An image cytometric technique is a concise method to detect adenoviruses and host cell proteins and to monitor the infection and cellular responses induced.

Authors:  Takao Morinaga; Thảo Thi Thanh Nguyễn; Boya Zhong; Michiko Hanazono; Masato Shingyoji; Ikuo Sekine; Yuji Tada; Koichiro Tatsumi; Hideaki Shimada; Kenzo Hiroshima; Masatoshi Tagawa
Journal:  Virol J       Date:  2017-11-10       Impact factor: 4.099

Review 7.  Autophagy in Tumor Immunity and Viral-Based Immunotherapeutic Approaches in Cancer.

Authors:  Ali Zahedi-Amiri; Kyle Malone; Shawn T Beug; Tommy Alain; Behzad Yeganeh
Journal:  Cells       Date:  2021-10-06       Impact factor: 7.666

Review 8.  Current landscape and perspective of oncolytic viruses and their combination therapies.

Authors:  Yinghan Su; Changqing Su; Lunxiu Qin
Journal:  Transl Oncol       Date:  2022-09-09       Impact factor: 4.803

Review 9.  Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways.

Authors:  Zhi Zhu; A J Robert McGray; Weijian Jiang; Binfeng Lu; Pawel Kalinski; Zong Sheng Guo
Journal:  Mol Cancer       Date:  2022-10-12       Impact factor: 41.444

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.